LoadingLoadingLoading34 funds hold it · Insiders net selling
Net selling: insiders sold $9.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Financial period
Q3 2026
Adjusted EPS
Company release
Revenue
Company release
Company GAAP EPS $0.93
EPS comparison unavailable.
Full Year 2026 guidance
$1.36B to $1.37B
No comparable estimate
Estimates as of Nov 11, 2026
EPS expected
-$0.51 to -$0.15
Revenue expected
17 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $0.29Company adjusted | Not comparableDifferent EPS measure | $361.0MCompany release | +36.1%from $265.2M |
| Jun 30, 2026Reported Jul 30, 2026 | $0.42Company adjusted | Not comparableDifferent EPS measure | $335.0MCompany release | +44.3%from $232.1M |
| Mar 31, 2026Reported May 7, 2026 | $0.45Company adjusted | Not comparableDifferent EPS measure | $301.7MCompany release | +48.3%from $203.5M |
| Dec 31, 2025Reported Feb 19, 2026 | -$0.50est. -$0.47 | -6.51%miss | $281.3MAlpha Vantage | +39.4%from $201.8M |
| Sep 30, 2025Reported Oct 29, 2025 | -$0.39est. -$0.49 | +20.41%beat | $265.2MSEC filing | +38.5%from $191.5M |
| Jun 30, 2025Reported Jul 30, 2025 | -$0.44est. -$0.51 | +13.73%beat | $232.1MSEC filing | +30.9%from $177.2M |
| Mar 31, 2025Reported Apr 30, 2025 | -$0.49est. -$0.59 | +16.95%beat | $203.5MSEC filing | +20.8%from $168.5M |
| Dec 31, 2024Reported Feb 20, 2025 | -$0.62est. -$0.50 | -23.06%miss | $201.8MAlpha Vantage | +30.2%from $155.1M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $281.3M | $301.7M | $335.0M | $361.0M |
| Cost of what it sold | $99.5M | $104.9M | $115.9M | $124.8M |
| Gross profit | $181.8M | $196.7M | $219.0M | $236.2M |
| What it spent | ||||
| Research and development | $98.3M | $91.0M | $96.5M | $100.8M |
| Sales and admin | $60.9M | $57.9M | $61.7M | $90.9M |
| Other operating costs | $143.4M | $169.1M | $190.0M | $177.2M |
| Total operating expenses | $302.6M | $318.1M | $348.1M | $368.9M |
| What was left | ||||
| Operating profit | -$120.8M | -$121.3M | -$129.1M | -$132.8M |
| Interest on debt | $1.2M | $1.3M | $1.3M | $1.3M |
| Profit before tax | -$130.2M | -$111.7M | -$120.0M | -$124.0M |
| Tax | -$1.7M | $372.0K | $185.0K | $343.0K |
| Net profit | -$128.5M | -$112.1M | -$120.1M | -$124.4M |
| EBITDA | -$119.0M | -$100.9M | -$109.0M | -$112.5M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Guardant Health, Inc. (GH) Seasonal returns chart
NeutralNov 6Guardant Health Stocks Fall 9.49% as Cash Burn Outlook Rises Despite 36% Growth
BearishNov 6TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent
BearishNov 6Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36% as Shield ...
BullishNov 6Guardant Health Q3 Results: Adjusted loss narrows 25% YoY to $(0.29)
BullishNov 6Guardant Health Stock Slides 12% After Cash Burn Forecast Widens Despite Revenue Beat
BearishNov 5Guardant Health falls 12% as cash burn guidance disappoints
BearishNov 5Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
Leans bullishNov 531 macro signals shaping GH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
